Immunohistochemical Expression of Inhibin Beta A (INHBA) in Colorectal Carcinoma
1 other identifier
observational
60
1 country
1
Brief Summary
A retrospective observational study to evaluate immunohistochemical expression of Inhibin Beta A (INHBA) in 60 cases of Colorectal Carcinoma, and compare levels of its expression to different clinicopathological criteria.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Jan 2021
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2021
CompletedFirst Submitted
Initial submission to the registry
March 20, 2023
CompletedFirst Posted
Study publicly available on registry
April 3, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 30, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
June 30, 2024
CompletedApril 3, 2023
March 1, 2023
2.7 years
March 20, 2023
March 20, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Detection of INHBA in Colorectal Carcinoma.
Detection of expression of INHBA in Colorectal Carcinoma cells by immunohistochemical approach, using anti-human INHBA monoclonal antibody.
6 months
Secondary Outcomes (1)
Correlation between INHBA expression in Colorectal Carcinoma and clinicopathological parameters.
6 months
Study Arms (1)
Participants
60 archived Formalin-fixed Paraffin-embedded tissue blocks of Colorectal Carcinoma will be obtained and sectioned. From each block; Two tissue sections will be prepared, one tissue section will be stained by Hematoxylin and Eosin to detect tumor phenotype and depth of invasion. Other tissue section will be immunohistochemically stained by Anti-Human INHBA.
Interventions
Staining of Colorectal Carcinoma tissue sections by monoclonal antibodies against human Inhibin Beta A by immunohistochemical procedures.
Eligibility Criteria
Archived Formalin-fixed, Paraffin-embedded tissue blocks belonged to patients suffered from colonic and/or rectal cancers. Patients were admitted to sohag university hospital and underwent colectomy and their colonic specimens were sent to Pathology Laboratory of the same hospital to ascertain diagnosis and tumor phenotype, from period Janurary 2021 to December 2022.
You may qualify if:
- Specimens from patients with Colorectal Carcinoma. Tissue blocks with sufficient material. Specimens with sufficient clinical data.
You may not qualify if:
- Tissue blocks with insufficient, destroyed or necrotic material. Specimens with insufficient clinical data.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Sohag Universitylead
Study Sites (1)
Sohag University hospitals
Sohag, Egypt
Biospecimen
60 formalin fixed, Paraffin embedded Colorectal Cancer tissue blocks.
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Teaching Assistant of Pathology
Study Record Dates
First Submitted
March 20, 2023
First Posted
April 3, 2023
Study Start
January 1, 2021
Primary Completion
September 30, 2023
Study Completion
June 30, 2024
Last Updated
April 3, 2023
Record last verified: 2023-03